21:51 , Sep 14, 2018 |  BioCentury  |  Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
17:28 , Sep 14, 2018 |  BC Week In Review  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
13:08 , Sep 12, 2018 |  BC Extra  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
17:46 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and...
21:22 , Sep 6, 2018 |  BC Extra  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also...
02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
22:22 , Jan 13, 2017 |  BioCentury  |  Emerging Company Profile

Conditional replication

Oncorus Inc. has devised a method to restrict replication of oncolytic viruses to tumor cells without deleting viral genes. The approach could create viruses that are more potent and selective than attenuated viruses in the...
20:30 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Oncorus completes venture financing

Oncorus raised an additional $4 million in a series A round from Astellas Venture Management, bringing the total raised in the round to $61 million. Oncorus Inc. , Cambridge, Mass. ...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in...